<DOC>
	<DOCNO>NCT01131676</DOCNO>
	<brief_summary>The aim present study investigate safety BI 10773 treatment patient Type 2 Diabetes Mellitus high cardiovascular risk .</brief_summary>
	<brief_title>BI 10773 ( Empagliflozin ) Cardiovascular Outcome Event Trial Type 2 Diabetes Mellitus Patients ( EMPA-REG OUTCOME ) .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent 2 . Male female patient diet exercise regimen drug naive pre treat background therapy . Antidiabetic therapy unchanged 12 week prior randomization . 3 . Glycosylated haemoglobin ( HbA1c ) &gt; = 7.0 % &lt; =10 % patient background therapy HbA1c &gt; = 7.0 % &lt; = 9.0 % drug naive patient 4 . Age &gt; = 18 year 5 . Body Mass index &lt; = 45 Visit 1 6 . Signed date informed consent 7 . High cardiovascular risk Exclusion criterion : 1 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second measurement ( day ) 2 . Indication liver disease , define serum level either alanine aminotransferase ( ALT ) , aspartate aminotransferase ALT alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen and/or run . 3 . Planned cardiac surgery angioplasty within 3 month 4 . Impaired renal function , define Glomerular Filtration Rate &lt; 30 ml/min ( severe renal impairment , Modification Diet Renal Disease formula ) screen run . 5 . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption 6 . Blood dyscrasia disorder cause haemolysis unstable Red Blood Cell ( e.g . malaria , babesiosis , haemolytic anemia ) 7 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year 8 . Contraindications background therapy accord local label 9 . Treatment antiobesity drug ( e.g . sibutramine , orlistat ) 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight 10 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except type 2 diabetes mellitus 11 . Premenopausal woman ( last menstruation &lt; + 1 year prior informed consent ) : nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems , oral , implantable injectable contraceptive , sexual abstinence , double barrier method vasectomise partner 12 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake 13 . Participation another trial investigational drug within 30 day prior inform consent 14 . Any clinical condition would jeopardize patient safety participate clinical trial 15 . Acute coronary syndrome , stroke TIA within 2 month prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>